China’s medtech influence is beginning to threaten the West’s dominance.
In addition to tax incentives in China, U.S. manufacturers are seeking Chinese partners due to a lack of domestic funding.
Tariffs on imports will hurt business expansion in Asia.
Devices that help treat respiratory problems are in high demand.
The country can’t ignore the fact that Asia is the future of medtech growth.
Don’t skimp on conducting due diligence.
How are you protecting your IP and keeping talent from going overseas?
Companies must be aware of the changing clinical trial regulatory environment for devices in China.
With differing cultural attitudes towards tissue donation and transplantation, be prepared for some complex hurdles.
Within this large and growing market, some companies are capitalizing, while others are faltering.